Clinical trial NCT05165459: Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers
Official title: Open Label Single Arm Proof of Concept Trial to Evaluate the Efficacy and Safety of Cytori Celution System in Chronic Non-Healing Venous Leg Ulcers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Venous Leg Ulcer
Autologous Adipose Stromal Vascular Fraction
Adipose-Derived Mesenchymal Stem Cells
Mesenchymal Stem Cells
Keywords: Cytori Celution System
Lead sponsor: Szeged University
Sponsor class: OTHER
First posted: 2021-12-21
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: To evaluate the efficacy and safety of Cytori Celution System in Hungarian patients with chronic non-healing venous leg ulcers.

Detailed description: This motive trial can help to establish routine application of this internationally widely used device at University of Szeged. The primary outcome is the reduction rate of the wound size. The treatment response will be calculated from wound size before and after treatment. Any adverse events related to the study device will be monitored.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent
2. Males or females age ≥ 18
3. At least one venous chronic leg ulcer with the following condition 3.1. Ulcer is present beyond 2 months 3.2. Conservative treatment not leading to improvement 3.3. Wound size between ≥5 and ≤100 cm2
4. Ability to safely undergo tissue harvest that is anticipated to yield \>100mL of adipose tissue at a site that is free from infection and injury
5. Able and willing to work with the doctor, adhere to therapeutic prescriptions and appear on prescribed examinations
6. Normal or clinically not significant abnormal values based on investigator judgement on white blood cell count (WBC), C-reactive protein (CRP), Platelets, international normalized ratio (INR), partial thromboplastin time (APTT), haemoglobin (Hgb), Renal and Liver function
7. Females of childbearing potential must have a negative pregnancy test at the Screen Visit
8. Females of childbearing potential must agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which has a proven low failure rate of less than 1%

Exclusion Criteria:

1. More than 20% change in surface area of target ulcer between screening and enrollment visit.
2. There is bone involvement in case of ulcer
3. Patient with a history of bleeding disorder
4. Therapy for anticoagulation
5. Patient receiving corticosteroids, immunosuppressive or cytotoxic agents, and all systemic agents that can affect wound repair
6. Patient with any treatment that might interfere with the assessment of the study treatment
7. Pregnant or likely to become pregnant or lactating women
8. Participation in any type of clinical investigation concurrently or in the last 6 months
9. Positive for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) and syphilis (results within 1 month are acceptable)
10. Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for the participation in the study.
11. Active cancer during chemotherapy or radiotherapy, or recent cancer, if the remission had place less than 5 years before joining the study (except basal cell skin cancer)
12. Patient currently undergoing dialysis for renal insufficiency (serum creatinine ≥2 mg/dL)
13. In the opinion of treating physician, patient not expected to survive beyond 30 days
14. Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance
15. Uncontrolled chronic disease
16. Patient with history of severe alcohol or drug abuse
17. Lack of patient's cooperation
18. Use with blood thinners within 8 weeks of enrollment
19. Systemic treatments with a possible effect on ulcers within 4 weeks prior to enrollment with the following exceptions:

    1. Ustekinumab (within 16 weeks prior to enrollment)
    2. Adalimumab, infliximab, alefacept (within 8 weeks prior to enrollment)

Primary outcomes:
measure: Reduction rate of the wound size
timeFrame: 28 days
Secondary outcomes:
measure: Wound closure at Day 28
timeFrame: 28 days
measure: Improvement of Quality of Life (QoL) - EQ-5D-5L
timeFrame: 28 days
measure: Improvement Wound pain
timeFrame: 28 days
Other outcomes:
Locations:
city: Szeged
country: Hungary
facility: University of Szeged Department of Dermatology and Allergology
Study officials:
affiliation: Szeged University
name: Balázs Bende, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Szeged University
name: Lajos Kemény, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. doi: 10.1080/14653240600855905.
citation: Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007 Nov;262(5):509-25. doi: 10.1111/j.1365-2796.2007.01844.x.
citation: Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.
citation: Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A; International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-5. doi: 10.1080/14653240500319234.
citation: Meng X, Sun B, Xue M, Xu P, Hu F, Xiao Z. Comparative analysis of microRNA expression in human mesenchymal stem cells from umbilical cord and cord blood. Genomics. 2016 Apr;107(4):124-31. doi: 10.1016/j.ygeno.2016.02.006. Epub 2016 Feb 26.
citation: Volz AC, Huber B, Kluger PJ. Adipose-derived stem cell differentiation as a basic tool for vascularized adipose tissue engineering. Differentiation. 2016 Jul-Aug;92(1-2):52-64. doi: 10.1016/j.diff.2016.02.003. Epub 2016 Mar 11.
citation: Zachar V, Rasmussen JG, Fink T. Isolation and growth of adipose tissue-derived stem cells. Methods Mol Biol. 2011;698:37-49. doi: 10.1007/978-1-60761-999-4_4.
citation: Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002 May;109(10):1291-302. doi: 10.1172/JCI15182.
citation: Tang Y, Yasuhara T, Hara K, Matsukawa N, Maki M, Yu G, Xu L, Hess DC, Borlongan CV. Transplantation of bone marrow-derived stem cells: a promising therapy for stroke. Cell Transplant. 2007;16(2):159-69.
citation: Aoi T, Stacey G. Impact of National and International Stem Cell Banking Initiatives on progress in the field of cell therapy: IABS-JST Joint Workshop: Summary for Session 5. Biologicals. 2015 Sep;43(5):399-401. doi: 10.1016/j.biologicals.2015.07.007. Epub 2015 Aug 24.